Mr. Yifftach Biel reports

DIAGNOSTEAR TECHNOLOGIES INC. ANNOUNCES UPSIZING OF PRIVATE PLACEMENT OF UNITS

Further to its press release from June 3, 2025, Diagnostear Technologies Inc.'s previously announced non-brokered private placement of units at a price of 50 cents per unit has been increased to up to two million units for aggregate gross proceeds of $1-million.

Each unit will consist of one common share of the company and one common share purchase warrant. Each warrant will be exercisable to purchase one common share at an exercise price of $1 for a term of 18 months from the closing date of the offering.

No finders' fees will be paid in connection with this offering.

The net proceeds of the offering will be used for the company's working capital and general corporate purposes.

Closing of the offering is anticipated to occur on or before Nov. 5, 2025, or such other date as may be determined by the company, subject to the receipt of investor documentation, funds and compliance with the requirements of the Canadian Securities Exchange.

All securities issued in connection with the offering will be subject to a statutory hold period expiring four months and one day after the issuance thereof.

About Diagnostear Technologies Inc.

Diagnostear is a leading ophthalmic company developing and commercializing disruptive diagnostic solutions for better management of eye diseases. Diagnostear's TeaRx technology is a diagnostic platform intended for rapid, point-of-care testing (POCT) of ophthalmic pathologies through multiparameter analysis of non-invasively collected tear fluid. The first CE-IVD (Conformite Europeenne in vitro diagnostic) and Israeli MoH-approved (Ministry of Health) test based on the TeaRx platform is intended for diagnosis of dry-eye syndrome (DES TeaRx Dry Eye). This product is not FDA (U.S. Food and Drug Administration) cleared yet. Beyond DES, Diagnostear is developing innovative tests based on the TeaRx platform for additional ophthalmic indications. Among others, Diagnostear's pipeline includes TeaRx Red Eye, the first test of its kind for differential assessment of adenoviral conjunctivitis, herpetic keratitis and allergic conjunctivitis.

We seek Safe Harbor.